<DOC>
	<DOCNO>NCT02765555</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability PK profile single dose 60mg RBO-7000 stable subject schizophrenia medication risperidone .</brief_summary>
	<brief_title>First Man Study Safety , Tolerability PK Profile RBP-7000</brief_title>
	<detailed_description>Twelve subject stable schizophrenia enrol . The expected duration participation 88 day include least 2 day screen 85 day treatment period ( 15 -day inpatient stay clinical unit additional 70-day outpatient period , include Day 85 end study follow early termination visit . Visits occur approximately weekly outpatient period . Neurological clinical symptom assessment ( Positive Negative Syndrome Scale [ PANSS ] , Clinical Global Impressions-Schizophrenic Specific [ CGI-SCH ] , Simpson-Angus Scale [ SAS ] , Barnes Akathisia Scale [ BAS ] , Columbia-Suicide Severity Rating Scale [ C-SSRS ] ) conduct screening , day admission clinical unit ( Day -1 ) , post-dose visit throughout study include follow-up visit . Scale result review Principal Investigator . The Abnormal Involuntary Movement Scale ( AIMS ) Tardive Dyskinesia perform screen post-dose visit throughout study include end study follow-up visit . CYP-2D6 genotyping conduct screening . Tolerability measure use SAS , conduct described . Blood sample assess PK parameter take pre-dose approximately 84 day post-dose . End study procedure conduct follow-up Day 85 ( 84 day post-dose ) early termination ( ET ) ass adverse event ( AEs ) ongoing last visit , new AEs develop , measurement safety parameter .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Confirmed diagnosis paranoid , residual , undifferentiated schizophrenia document letter subject 's psychiatrist primary care provider . Clinically stable subject ( subject Principal Investigator ( PI ) establish medical record history subject least one reliable informant resides subject , subject clinically stable least 60 day without hospitalization ) eligible participate study . Subjects body mass index ( BMI ) 18 33 kg/m2 inclusive weigh least 49.9 kg eligible entry . Subjects give write informed consent . Subjects take risperidone product last 60 day prior study screen . Subjects history cancer ( exclude resect basal cell squamous cell carcinoma skin ) unless disease free ≥ 5 year . Subjects another active medical condition organ disease may either compromise subject safety interfere safety and/or outcome evaluation study drug . This include , limit follow abnormality : total bilirubin &gt; 2.5 mg/dL ( 51 μmol/L ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 time upper limit normal ( ULN ) clinically significant serum creatinine &gt; 2 x ULN , international normalize ratio ( INR ) ≥ 2.0 . Other exclude medical condition include , limited , history heart attack , brain injury , low blood pressure clinically significant irregular heartbeat . Subjects know diagnosis type 1 2 diabetes subject abnormal Hemoglobin A1c ( HbA1c ) screening . Subjects clinically significant comorbidities could affect nearterm survival . Subjects treat investigational drug within 30 day begin study screen . Subjects significant traumatic injury , major surgery open biopsy within past 4 week . Subjects receive opioid opioidcontaining analgesic . Subjects consume &gt; 1 alcoholic drink per day within last 30 day ( defined one ounce 80 proof spirit , 12 ounce beer , 4 ounce wine ) . Subjects prior allergic reaction sensitivity component RBP7000 . Subjects concurrent uncontrolled illness may interfere ability participate trial . Subjects know contraindication sensitivity risperidone component RBP7000 . Women positive pregnancy test screening . Women childbearing potential , pregnant lactating , seek pregnancy , fail take adequate contraceptive precaution , ( e.g. , oral injectable contraceptive , approve hormonal implant topical patch , intrauterine device , abstinence . Should female subject become sexually active , must agree use double barrier method barrier plus spermicide ) . A woman childbearing potential define female less 2 year postmenopausal undergone hysterectomy surgical sterilization , e.g . bilateral tubal ligation , bilateral ovariectomy ( oophorectomy ) . . Subjects positive urine drug screen opiate , cocaine , amphetamine , methadone , marijuana , barbiturate , benzodiazepine , methamphetamine , phencyclidine , tricyclic antidepressant unless positive screen determine secondary allowable concomitant medication . Subjects epilepsy seizure disorder , Parkinson 's disease , dementia . Subjects take buproprion , chlorpheniramine , cimetidine , clomipramine , doxepin , quinidine . Subjects take clozapine , phenothiazine , haloperidol . Subjects take serotonin reuptake inhibitor ( e.g. , fluoxetine , paroxetine ) 30 day prior begin study screen . . Subjects take medication , addition list , may expect significantly interfere metabolism excretion risperidone and/or 9hydroxyrisperidone , may associate significant drug interaction risperidone , may pose significant risk subject ' participation study . Subjects previously enrol study . Subjects unable , opinion Principal Investigator , comply fully study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>